{"id":"W4415711778","doi":"10.1016/j.jtocrr.2025.100929","title":"Patient-Reported Symptoms and Quality of Life With Sacituzumab Govitecan Versus Docetaxel in Metastatic NSCLC: The Phase 3, Randomized EVOKE-01 Trial","year":2025,"lang":"en","type":"article","venue":"JTO Clinical and Research Reports","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"Zymeworks (Canada)","funders":"Gilead UK and Ireland Corporate Contributions; Gilead Sciences","keywords":"Docetaxel; Quality of life (healthcare); Randomized controlled trial; Phases of clinical research; Chemotherapy; Exploratory analysis","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002159602,0.001009943,0.001912515,0.0002284254,0.0002482391,0.0009848643,0.0007522986,0.001083385,0.002377475],"category_scores_gemma":[0.001529004,0.000308393,0.001827429,0.0003706776,0.0007255255,0.0006060165,0.0003051007,0.002256186,0.0003764523],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007738722,"about_ca_system_score_gemma":0.0008813929,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006052944,"about_ca_topic_score_gemma":0.001716381,"domain_scores_codex":[0.9992612,0.0004799486,0.00003720629,0.00008966352,0.00006776275,0.00006425066],"domain_scores_gemma":[0.9991181,0.0002654889,0.000265689,0.00007183143,0.00004697532,0.0002319236],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9666497,0.004261102,0.003792357,0.0005430597,0.001619597,0.00005169643,0.00005184192,0.0009291732,0.002372936,0.0001233062,0.001242631,0.01836265],"study_design_scores_gemma":[0.9002702,0.0848848,0.01069826,0.00004992474,0.001227219,0.0001321606,0.00003119979,0.000969672,0.0006026888,0.0002415367,0.0008682224,0.00002405527],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9941859,0.003100742,0.0001634935,0.0003032322,0.0001158215,0.0005632152,0.0006060664,0.00003326099,0.0009283561],"genre_scores_gemma":[0.9953141,0.001216635,0.0003437001,0.0004422932,0.000153618,0.0007987953,0.001050952,0.00001080622,0.000669075],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002377475,"threshold_uncertainty_score":0.01142114,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1552045560590042,"score_gpt":0.5380789188335684,"score_spread":0.3828743627745642,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}